Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Infographics

Hospital systems will be in a precarious position if they all aim for the same North Star. What might their evolution look like in coming years?

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Natural language processing is the perfect example of how AI can maximize people's talents, impact, and value. But its potential is just being realized.

Vice President of Technology, Optum

A detailed look at the 22 new payer-provider partnerships created in Q1 this year.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Oliver Wyman
Senior Consultant, Health & Life Sciences, Oliver Wyman

Why a focus on the provider is needed to achieve 4 or 5 Stars.

Principal, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Earlier this year, we analyzed payer-provider partnerships. As 2017 comes to a close, we consider the year's steady growth and new twists.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Oliver Wyman

Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.

Principal, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Survey responses confirm that CSR defunding would have a significant impact on 2018 rates and payers’ continued participation in the ACA exchanges.

Partner, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

Insights in your inbox

Subscribe